Viaskin® Peanut (DBV712) Expanded Access Protocol in Peanut-Allergic Children
Latest Information Update: 31 May 2021
At a glance
- Drugs Peanut allergy immunotherapy (Primary)
- Indications Peanut hypersensitivity
- Focus Expanded access; Therapeutic Use
- Sponsors DBV Technologies
Most Recent Events
- 26 May 2021 Status changed from recruiting to completed.
- 05 May 2020 New trial record